In 60 cases of PTC with 2 to 4 discrete tumor foci, each focus was tested for BRAF, NRAS, HRAS, and KRAS point mutations and RET/PTC1 and RET/PTC3 rearrangements and analyzed for various histopathologic features.     ///    "Overall, BRAF mutations were found in 43% of tumors, RAS in 27%, and RET/PTC in 2%. "